Search results
Results From The WOW.Com Content Network
p-Phenylenediamine (PPD) is an organic compound with the formula C 6 H 4 (NH 2) 2. This derivative of aniline is a white solid, but samples can darken due to air oxidation. [ 1 ] It is mainly used as a component of engineering polymers and composites like kevlar .
This is a list of chemotherapeutic agents, also known as cytotoxic agents or cytostatic drugs, that are known to be of use in chemotherapy for cancer.This list is organized by type of agent, although the subsections are not necessarily definitive and are subject to revision.
Osteoporosis, including drug- and cancer-related osteoporosis, giant cell tumour of bone and hypercalcaemia of malignancies: Hypercholesterolaemia, cataract, urinary retention, hypocalcaemia, osteonecrosis of the jaw and anaphylaxis. Gemtuzumab ozogamicin: IV: CD33 antibody that induces apoptosis of the tagged cell. Acute myeloid leukaemia
Cancer is a group of diseases that involve abnormal increases in the number of cells, with the potential to invade or spread to other parts of the body. [1] Not all tumors or lumps are cancerous; benign tumors are not classified as being cancer because they do not spread to other parts of the body. [ 1 ]
Pages for logged out editors learn more. Contributions; Talk; Para-phenylenediamine
This list of pharmaceutical compound number prefixes provides codes used by individual pharmaceutical companies when naming their pharmaceutical drug candidates. . Pharmaceutical companies generally produce large numbers of compounds in the research phase for which it is impractical to use often long and cumbersome systematic chemical names, and for which the effort to generate nonproprietary ...
Phenylenediamine may refer to: o-phenylenediamine or OPD, a chemical compound C 6 H 4 (NH 2) 2; m-phenylenediamine or MPD, a chemical compound C 6 H 4 (NH 2) 2; p-phenylenediamine or PPD, a chemical compound C 6 H 4 (NH 2) 2; N,N-dimethyl-p-phenylenediamine or DMPD; N,N,N′,N′-tetramethyl-p-phenylenediamine or TMPD, used in microbiology; N,N ...
Blinatumomab linking a T cell to a malignant B cell.. Blinatumomab is a bispecific T-cell engager (BiTE). [7] It enables a patient's T cells to recognize malignant B cells. A molecule of blinatumomab combines two binding sites: a CD3 site for T cells and a CD19 site for the target B cells.